PET Imaging of Estrogen Receptors Using 18F-Based Radioligands.
Sign Up to like & getrecommendations! Published in 2022 at "Methods in molecular biology"
DOI: 10.1007/978-1-0716-1920-9_9
Abstract: In vivo molecular imaging of estrogen receptor alpha (ER) can be performed via positron emission tomography (PET) using ER-specific radioligands, such as 16α-[18F]fluoro-17β-estradiol (18F-FES). 18F-FES is a radiopharmaceutical recently approved by the United States Food… read more here.
Keywords: fes pet; pet imaging; imaging estrogen; 18f fes ... See more keywords
[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Imaging and Biology"
DOI: 10.1007/s11307-025-02015-2
Abstract: This study examines the combination of FES-PET and FDG-PET as complementary imaging for detection of metastatic ILC. We retrospectively evaluated FES and FDG uptake in patients with metastatic ILC from an estrogen receptor (ER) positive… read more here.
Keywords: fdg pet; fdg; fes pet; pet ... See more keywords
Update on 18F-Fluoroestradiol.
Sign Up to like & getrecommendations! Published in 2024 at "Seminars in nuclear medicine"
DOI: 10.1053/j.semnuclmed.2024.09.001
Abstract: 18F-16α-Fluoroestradiol (18F-FES) is a radiolabeled estrogen analogue positron emission tomography (PET) imaging agent that binds to the estrogen receptor (ER) in the nucleus of ER-expressing cells. Proof-of-concept studies of 18F-FES demonstrated expected correlation between tumoral… read more here.
Keywords: breast cancer; fes pet; 18f fluoroestradiol; 18f fes ... See more keywords
18F-FES PET/CT for Characterization of Brain and Leptomeningeal Metastasis in Double Primary Cancer Patient.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004197
Abstract: ABSTRACT The clinical value of 16α-18F-fluoro-17 β-estradiol (18F-FES) PET in breast cancer has been widely investigated because it can visualize estrogen receptor-expressing lesions. This relatively new radiotracer adds clinical values by characterization of metastasis in… read more here.
Keywords: 18f fes; fes pet; brain; metastasis double ... See more keywords
FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-2380
Abstract: With great interest, we read the article by Kurland and colleagues ([1][1]) that investigates the value of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET for the prediction of progression-free survival (PFS) in 84 patients with advanced,… read more here.
Keywords: pfs; pet; fes pet; fdg pet ... See more keywords
Abstract PO4-19-03: FES-PET/MRI for Tailored treatment of luminal A and lobular breast cancer: a prospective cohort study
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po4-19-03
Abstract: Background: Breast cancer (BC) staging is essential to planning the most appropriate treatment pathway. Currently, BC management has become more tailored to the tumor’s and patient’s characteristics. However, BC imaging shows varying performance according to… read more here.
Keywords: cancer; cohort; pet mri; mri ... See more keywords
Abstract PS11-01: [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-ps11-01
Abstract: Background: Multiple single institution studies have shown that FES-PET predicts clinical benefit of endocrine based therapy for patients with metastatic breast cancer (MBC). ECOG-ACRIN trial EAI142 is a multicenter imaging biomarker study of FES-PET to… read more here.
Keywords: breast cancer; fes pet; therapy;
Abstract PS11-03: Comparative analysis of [18F]FES- and [18F]FDG-PET in patients with metastatic ER+ lobular breast cancer
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-ps11-03
Abstract: BACKGROUND: Detection of invasive lobular carcinoma (ILC) with standard imaging modalities can be challenging. [18F]fluorodeoxyglucose (FDG) PET is commonly used in the work up of first presentation of metastatic breast cancer (MBC), but may be… read more here.
Keywords: pet; cancer; fdg pet; fes pet ... See more keywords
Clinical utility of [ 18 F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.1059
Abstract: 1059 Background: Second line treatment options for patients with ER+/HER2- metastatic breast cancer (MBC) after progression on 1 st line endocrine therapy (ET) continue to expand with novel endocrine agents (oral SERDs) and combination therapies… read more here.
Keywords: line treatment; line; fes uptake; fes pet ... See more keywords
Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00400
Abstract: PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[18F]fluoro-17β-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity… read more here.
Keywords: metastasis; 18f fes; fes pet; status ... See more keywords
The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies.
Sign Up to like & getrecommendations! Published in 2021 at "Quantitative imaging in medicine and surgery"
DOI: 10.21037/qims-20-1364
Abstract: Background For patients with previously diagnosed dual primary tumors, it is usually difficult to determine the diagnosis and treatment of stage IV recurrence. The study was to explore the influences of 18F-fluoroestradiol positron emission tomography/computed… read more here.
Keywords: fes pet; treatment; dual primary; 18f fluoroestradiol ... See more keywords